Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK
Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK
Ideaya与葛兰素史克合作提名潜在的一流Pol Theta解旋酶抑制剂
- Ideaya Biosciences Inc (NASDAQ:IDYA) has selected a potential first-in-class Pol Theta Helicase development candidate, a small molecule inhibitor of the helicase domain of DNA Polymerase Theta.
- Ideaya is collaborating with GSK plc (NYSE:GSK) on IND-enabling studies to support the evaluation of the Pol Theta Helicase candidate in combination with niraparib, GSK's PARP inhibitor, in tumors with BRCA or other homologous recombination mutations or homologous recombination deficiency.
- The companies are targeting an IND submission for the Pol Theta Helicase DC in the first half of 2023.
- Also Read: Ideaya Biosciences' IDE397 Shows Preliminary Tolerability In Early-Stage Solid Tumor Trial.
- GSK will lead clinical development for the Pol Theta program. It holds a global license to develop and commercialize the Pol Theta Helicase candidate. It is responsible for all R&D costs for the program, including those incurred by IDEAYA.
- IDEAYA is eligible to receive a milestone payment of up to $485 million.
- Upon potential commercialization, IDEAYA will be eligible to receive up to $475 million of commercial milestones.
- Price Action: IDYA shares closed at $13.61 on Monday, and GSK stock is up 0.16% at $43.77 during the premarket session on the last check Tuesday.
- Ideaya生物科学公司纳斯达克(Sequoia Capital：IDYA)选择了一种潜在的一流Pol Theta解旋酶开发候选者，这是一种DNAPolymerase Theta解旋酶域的小分子抑制剂。
- Ideaya 正在与葛兰素史克(纽约证券交易所股票代码：GSK)关于IND使能研究支持Pol Theta解旋酶候选与GSK的PARP抑制剂niraparib联合治疗BRCA或其他同源重组突变或同源重组缺陷的肿瘤的评估。
- 这两家公司的目标是在2023年上半年为Pol Theta解旋酶DC提交IND。
- 另请阅读： IDEAYA生物科学公司的IDE397在早期实体瘤试验中显示出初步耐受性.
- 葛兰素史克将领导Pol Theta计划的临床开发。它拥有开发Pol Theta解旋酶候选并将其商业化的全球许可证。它负责该项目的所有研发费用，包括IDEAYA产生的费用。
- IDEAYA有资格获得高达4.85亿美元的里程碑付款。
- 在潜在的商业化后，IDEAYA将有资格获得高达4.75亿美元的商业里程碑。
- 价格行动：IDYA股价周一收于13.61美元，葛兰素史克股价周二盘前上涨0.16%，至43.77美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。